Introduction {#S0001}
============

Deep sternal wound infection (DSWI) is one of the most serious complications after cardiac surgery procedures. According to the literature, frequency of DSWI after cardiac surgery is from 0.5% to 5.3% with the early in hospital mortality range from 10% to 47% \[[@CIT0001]--[@CIT0004]\]. Deep sternal wound infection also increases the length of hospital stay, short- and long-term morbidity and medical costs \[[@CIT0001], [@CIT0004]--[@CIT0007]\].

It is suggested that major mechanisms of DSWI are ischemia, hypoxia and nosocomial infections \[[@CIT0007], [@CIT0008]\]. Current standard medical therapy for DSWI includes antibiotics, surgical debridement, resuturing or negative pressure wound therapy (NPWT). Unfortunately, in some cases, these methods are insufficient and additional therapeutic options are needed.

In recent years hyperbaric oxygen therapy (HBO2) has become an approved treatment of patients with chronic, non-healing or difficult wounds. During HBO2 a short term of high pressure oxygen and atmospheric air is used to achieve hyperoxygenation of tissue. The dosage limits are determined by the toxicity of the O~2~ to the brain cells. The number of therapeutic sessions depends on the patient\'s clinical status and the type of treated disorder.

Hyperbaric oxygen therapy has a few different mechanisms improving wound healing, including anti-inflammatory effects, down-regulation of the cell adhesion molecules and diminished influence of leukocytes on the endothelium. Additionally, leukocyte killing capacity is enhanced, anaerobic bacteria are unable to grow, and production of clostridial α toxin is stopped. Hyperbaric oxygen therapy improves angiogenesis and vasculogenesis, and causes vasoconstriction and edema reduction. A wide range of growth factors and processes (e.g. cellular collagen synthesis) are stimulated by the availability of O~2~ in the cell matrix \[[@CIT0009]\].

Aim {#S0002}
===

There are only a few papers about HBO2 therapy in patients with DSWI after a cardiac surgery procedure. The aim of this study was to present the effects and usefulness of HBO2 therapy in patients with deep sternal wound infections after a cardiac surgery operation.

Material and methods {#S0003}
====================

In the period 2010--2012, ten patients who developed DSWI after cardiac surgery procedures were enrolled in the study. All data were collected retrospectively. Patients' characteristic are summarized in [Table I](#T0001){ref-type="table"}.

###### 

Patients' characteristics

  ------------------------------------------------------------------
  Parameter                               Result
  --------------------------------------- --------------------------
  Gender                                  60% male: 40% female

  Age                                     Mean: 63 (range: 53--78)

  BMI \[kg/m^2^\]                         30.3 (range: 24.8--33.5)

  Procedure                               Isolated CABG -- 40%\
                                          CABG + AVR -- 20%\
                                          CABG + MV repair -- 20%\
                                          CABG + MVR -- 10%\
                                          Debranching -- 10%

  Hypertension                            80%

  Diabetes mellitus                       50%

  Hyperlipidemia                          50%

  Atrial fibrillation                     20%

  Renal failure                           10%

  COPD                                    10%

  Peripheral vessel disease               10%

  Hepatitis C                             10%

  EuroSCORE II                            5.86 (range: 2--15.8)

  STS SCORE                               2.167% (range: 0.4--3.4)

  STS infection PREOPERATIVE risk score   7.6% (range: 1.9--11.4)

  STS infection COMBINED risk score       5.76% (range: 1.3--10.7)
  ------------------------------------------------------------------

Deep sternal wound infection was diagnosed according to the following criteria defined by the Centers for Disease Control and Prevention \[[@CIT0010]\]: 1 -- an organism isolated from culture of mediastinal tissue or fluid; 2 -- evidence of mediastinitis seen during operation; or 3 -- presence of chest pain, sternal instability, or fever (\>38°C), and either purulent drainage from the mediastinum, isolation of an organism present in a blood culture, or culture of the mediastinal area.

All patients were readmitted to hospital due to sternal dehiscence. Wound swabs were collected and empiric antibiotic therapy was indicated. In all cases culture reports and antibiotic susceptibility tests showed mixed multi-resistant bacterial or bacterial-fungal flora contaminations. Targeted antibiotic therapy was performed. The bacteriology data are presented in [Table II](#T0002){ref-type="table"}.

###### 

Microorganisms isolated from the patients' wound swabs

  Pathogen                            Percent of infected patients
  ----------------------------------- ------------------------------
  *Staphylococcus epidermidis* MRS    80
  *Klebsiella pneumoniae* ESBL        20
  *Enterobacter cloacae* ESBL         20
  *Staphylococcus aureus* MSSA        20
  *Staphylococcus haemolyticus* MRS   20
  *Staphylococcus hominis* MRS        20
  *Streptococcus agalactiae*          10
  *Klebsiella ornithinolytica* ESBL   10
  *Serratia marcescens*               10
  *Pseudomonas aeruginosa*            10
  *Enterococcus faecium*              10
  *Acinetobacter baumannii*           10
  *Acinetobacter haemolyticus*        10
  *Clostridium difficile*             10
  *Corynebacterium jeikeium*          10
  *Corynebacterium amycolatum*        10
  *Pediococcus pentosaceus*           10
  *Bacillus* spp.                     10
  *Candida albicans*                  10
  *Candida parapsilosis*              10
  *Staphylococcus aureus* MRS         10
  *Staphylococcus epidermidis* MSS    10

Beside the targeted antibiotic, every patient underwent surgical sternal debridement and NPWT. The decision of additional HBO2 therapy was made after 3 months of ineffective conventional therapy.

Hyperbaric oxygen therapy was performed in a multiplace hyperbaric chamber at Lesser Poland Center of Hyperbaric Therapy, Rydygier Hospital in Cracow. Hyperbaric oxygen therapy sessions were performed daily from Monday to Friday with a break of 2 days. A total of 20 sessions were performed, each 92 minutes long.

Results {#S0004}
=======

After 20 sessions of HBO2 therapy (4 weeks of treatment), 7 (70%) patients presented complete wound healing with fibrous scar formation. One patient was qualified for another cycle of HBO2 therapy with 20 additional sessions, and after that complete wound healing with fibrous scar formation was observed.

In 2 cases, patients received 5 and 19 of 20 sessions; however, the HBO2 course was interrupted because of improper qualifications for HBO2 therapy. In both patients the sternum was completely destroyed by osteitis and the patients were qualified for sternal reconstructions with a musculocutaneous flap surgery procedure.

During HBO2 therapy no complications were observed. [Figures 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"} present wounds before and after HBO2 therapy.

![**A** -- Male patient before HBO2 therapy, **B** -- the same male patient after HBO2 therapy](KITP-13-28407-g001){#F0001}

![**A** -- Female patient before HBO2 therapy, **B** -- the same female patient after HBO2 therapy](KITP-13-28407-g002){#F0002}

Discussion {#S0005}
==========

The incidence of postoperative DSWJ after cardiac surgery is rather low and ranges from 0.5% to 5.3% \[[@CIT0001]--[@CIT0004], [@CIT0011], [@CIT0012]\]. However, DSWI is one of the most serious complications, significantly increasing postoperative mortality, morbidity, time of hospitalization, hospital costs and need for surgical re-intervention \[[@CIT0013]\]. According to the literature, many factors have been found as DSWI risk factors and only some of them are modifiable \[[@CIT0014]--[@CIT0016]\]. Moreover, nowadays cardiac surgery patients mostly have at least two risk factors for postoperative DSWI because of their older age and comorbidities \[[@CIT0017]\].

Currently, debridement, directed antibiotics and NPWT are standard treatments in DSWI. Importantly, additional therapy algorithms may vary among surgeons. Past treatment options have included closed suction and continuous irrigation. Current paradigms in the management of sternal wound infection include surgical debridement, vacuum-assisted closure therapy, flap coverage, and sternal plating \[[@CIT0018]\]. Unfortunately, in the available literature there is still insufficient information about hyperbaric oxygen therapy as an alternative treatment option in DSWI \[[@CIT0001], [@CIT0002]\].

Hyperbaric oxygen therapy is widely used in surgery, with benefits observed in wound healing and limb salvage such as traumatic brain injury, chronic wounds, diabetic wounds, arterial ulcers, stasis ulcers, limb amputations, calciphylaxis, intractable vasculitic ulcers and others \[[@CIT0019]\]. Hyperbaric oxygen therapy is defined as compression of the whole body with at least 1.4 atmospheres absolute pressure of pure oxygen \[[@CIT0020]\]. Oxygen pressure increases and promotes collagen matrix formation, angiogenesis, cytoprotection, osteoclast/osteoblast activity and bone union, improves the effect of neutrophil response and increases the synergistic effect of antibiotics \[[@CIT0021]--[@CIT0024]\].

It has been shown that sternal ischemia and hypoxia may play a main role in indication of DSWI \[[@CIT0002], [@CIT0008], [@CIT0009]\]. For that reason the mechanism of HBO2 therapy may bring potential healing benefits. In our study, HBO2 therapy as an additional treatment in DSWI was successful in 80% of cases. Two cases were unsuccessful (20%) because of the completely destroyed sternum and wrong qualification for HBO2 therapy.

In our study, the decision of HBO2 therapy was based on the physician\'s personal clinical decision after 3 months of ineffective treatment. The extended 3-month period in our department was due to the qualifying period of ineffective treatment that must elapse to receive reimbursement for HBO2 treatment. However, it should be emphasized that in the author\'s opinion HBO2 therapy should be started when there is the first clinical evidence that standard methods of treatment in DSWI are insufficient.

In the literature, the timing of HBO2 therapy varied depending on the performed study. Barili *et al*. started HBO2 therapy after diagnosis of DSWI \[[@CIT0025]\]; Yu *et al*. started HBO2 2 weeks to months after DSWI diagnosis \[[@CIT0002]\], Higuchi *et al*. reported the initiation of HBO2 therapy for patients with persistent osteomyelitis after standard treatment \[[@CIT0026]\]. However, the timing of HBO2 therapy for DSWI has been discussed, and all performed studies, including our results, present very good clinical results.

It should be mentioned that in all patients the conventional LIMA harvesting was done by opening the cadaver\'s chest with a mid-sternotomy incision in the CABG procedure. Studies and investigational experiments showed that the internal mammary artery (IMA) is one of the most important risk factors of DSWI because of the IMA\'s role in the blood supply of the sternum \[[@CIT0008]\].

Currently, there are no guidelines or official clinical indications of HBO2 therapy in DSWI. There are only a few cases reports \[[@CIT0002], [@CIT0025], [@CIT0026]\] and no randomized controlled trials \[[@CIT0001], [@CIT0027], [@CIT0028]\] to support or reject the use of HBO2 in DSWI. Most of the published articles present level V evidence, which provides weak evidence to support the use of HBO2 in treatment, although the obtained results are encouraging \[[@CIT0007]\]. What is also important, one of the main limitations of HBO2 therapy is the distance between hyperbaric units and the cardiac surgery center. In our center we started to perform HBO2 therapy as additional treatment in DSWI shortly after the hyperbaric units were established in our town.

In our opinion, the potential benefits of HBO2 therapy as an additional treatment in DSWI are that it is a non-invasive, non-burdensome and safe procedure. However, to confirm or refute the benefits of HBO2 therapy further, a blinded randomized controlled trial on a large group of patients is needed.

Our study had several limitations. First, the number of cases was small. Second, there was no control group. Third, we performed a retrospective study; therefore some data may be missing or poorly documented. Fourth, the authors focused only on the clinical outcomes of studied patients.

Conclusions {#S0006}
===========

In this retrospective study, performed on a small group of patients, HBO2 as an additional therapy in deep sternal wound infections was successful in 80% of cases. It improves sternum stabilization, wound sterilization and final healing. No complications of HBO2 therapy were observed. HBO2 is an alternative way of treatment but definitely worth considering, especially in patients in whom standard pharmacotherapy and NPWT have failed. However, due to the small number of published studies on a very small number of patients, randomized, clinical trials are needed to assess the clinical results of HBO2 in DSWI after cardiac surgery procedures.
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